Skip to main content
NCBI home page
British Journal of Clinical Pharmacology logoLink to British Journal of Clinical Pharmacology
. 1989;27(Suppl 2):205S–209S. doi: 10.1111/j.1365-2125.1989.tb03483.x

The influence of food on the pharmacokinetics and ACE inhibition of cilazapril

J W Massarella, T M DeFeo, A N Brown, A Lin, R J Wills
PMCID: PMC1379749  PMID: 2527534

Abstract

1 The influence of food on the pharmacokinetics and angiotensin-converting enzyme (ACE) inhibitory effects of oral 5 mg doses of cilazapril was investigated in a two-way crossover study in 16 volunteers.

2 Plasma and urine concentrations of cilazaprilat, the active diacid metabolite of cilazapril, and plasma ACE activity were determined by a radio-enzymatic method.

3 Cmax decreased by 30% (P < 0.05) with a delay in tmax of 1 h (P < 0.05) and area under curve (AUC) was decreased by 14% (P < 0.05). The elimination rate was unaltered.

4 Onset of ACE inhibition was delayed by ≈ 30 min but degree and duration were unaffected.

5 The effect of food on the bioavailability of cilazapril at this dose would not be expected to be clinically significant.

Keywords: cilazapril, pharmacokinetics, ACE inhibition

Full text

PDF
205S

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Ajayi A. A., Elliott H. L., Reid J. L. The pharmacodynamics and dose-response relationships of the angiotensin converting enzyme inhibitor, cilazapril, in essential hypertension. Br J Clin Pharmacol. 1986 Aug;22(2):167–175. doi: 10.1111/j.1365-2125.1986.tb05245.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Colburn W. A., Gibson D. M., Wiens R. E., Hanigan J. J. Food increases the bioavailability of isotretinoin. J Clin Pharmacol. 1983 Nov-Dec;23(11-12):534–539. doi: 10.1002/j.1552-4604.1983.tb01800.x. [DOI] [PubMed] [Google Scholar]
  3. Fasanella d'Amore T., Bussien J. P., Nussberger J., Waeber B., Turini G. A., Brunner H. R., Kler L., Francis R. J. Effects of single doses of the converting enzyme inhibitor cilazapril in normal volunteers. J Cardiovasc Pharmacol. 1987 Jan;9(1):26–31. [PubMed] [Google Scholar]
  4. Ferry J. J., Horvath A. M., Sedman A. J., Latts J. R., Colburn W. A. Influence of food on the pharmacokinetics of quinapril and its active diacid metabolite, CI-928. J Clin Pharmacol. 1987 May-Jun;27(5):397–399. doi: 10.1002/j.1552-4604.1987.tb03037.x. [DOI] [PubMed] [Google Scholar]
  5. Francis R. J., Brown A. N., Kler L., Fasanella d'Amore T., Nussberger J., Waeber B., Brunner H. R. Pharmacokinetics of the converting enzyme inhibitor cilazapril in normal volunteers and the relationship to enzyme inhibition: development of a mathematical model. J Cardiovasc Pharmacol. 1987 Jan;9(1):32–38. [PubMed] [Google Scholar]
  6. Hauck W. W., Anderson S. A new statistical procedure for testing equivalence in two-group comparative bioavailability trials. J Pharmacokinet Biopharm. 1984 Feb;12(1):83–91. doi: 10.1007/BF01063612. [DOI] [PubMed] [Google Scholar]
  7. Hefti F., Fischli W., Gerold M. Cilazapril prevents hypertension in spontaneously hypertensive rats. J Cardiovasc Pharmacol. 1986 May-Jun;8(3):641–648. doi: 10.1097/00005344-198605000-00030. [DOI] [PubMed] [Google Scholar]
  8. Holck M., Fischli W., Hefti F., Gerold M. Cardiovascular effects of the new angiotensin-converting-enzyme inhibitor, cilazapril, in anesthetized and conscious dogs. J Cardiovasc Pharmacol. 1986 Jan-Feb;8(1):99–108. doi: 10.1097/00005344-198601000-00016. [DOI] [PubMed] [Google Scholar]
  9. Melander A. Influence of food on the bioavailability of drugs. Clin Pharmacokinet. 1978 Sep-Oct;3(5):337–351. doi: 10.2165/00003088-197803050-00001. [DOI] [PubMed] [Google Scholar]
  10. Mojaverian P., Rocci M. L., Jr, Vlasses P. H., Hoholick C., Clementi R. A., Ferguson R. K. Effect of food on the bioavailability of lisinopril, a nonsulfhydryl angiotensin-converting enzyme inhibitor. J Pharm Sci. 1986 Apr;75(4):395–397. doi: 10.1002/jps.2600750416. [DOI] [PubMed] [Google Scholar]
  11. Mäntylä R., Männistö P. T., Vuorela A., Sundberg S., Ottoila P. Impairment of captopril bioavailability by concomitant food and antacid intake. Int J Clin Pharmacol Ther Toxicol. 1984 Nov;22(11):626–629. [PubMed] [Google Scholar]
  12. Rakhit A., Hurley M. E., Redalieu E., Kochak G., Tipnis V., Coleman J., Rommel A. Effect of food on the bioavailability of pentopril, an angiotensin-converting-enzyme inhibitor, in healthy subjects. J Clin Pharmacol. 1985 Sep;25(6):424–428. doi: 10.1002/j.1552-4604.1985.tb02870.x. [DOI] [PubMed] [Google Scholar]
  13. Singhvi S. M., McKinstry D. N., Shaw J. M., Willard D. A., Migdalof B. H. Effect of food on the bioavailability of captopril in healthy subjects. J Clin Pharmacol. 1982 Feb-Mar;22(2-3):135–140. doi: 10.1002/j.1552-4604.1982.tb02661.x. [DOI] [PubMed] [Google Scholar]
  14. Swanson B. N., Vlasses P. H., Ferguson R. K., Bergquist P. A., Till A. E., Irvin J. D., Harris K. Influence of food on the bioavailability of enalapril. J Pharm Sci. 1984 Nov;73(11):1655–1657. doi: 10.1002/jps.2600731146. [DOI] [PubMed] [Google Scholar]
  15. Welling P. G. Influence of food and diet on gastrointestinal drug absorption: a review. J Pharmacokinet Biopharm. 1977 Aug;5(4):291–334. doi: 10.1007/BF01061694. [DOI] [PubMed] [Google Scholar]

Articles from British Journal of Clinical Pharmacology are provided here courtesy of British Pharmacological Society

RESOURCES